Navigation Links
DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan,PDT to Treat Esophage al Dysplasia

Researchers' Study Shows Promising Treatment for People Suffering from Barrett's Esophagus, a Leading Cause of Esophageal Cancer

WILMINGTON, MASSACHUSETTS--(CCNMatthews - May 17, 2007) - DUSA Pharmaceuticals, Inc. (NASDAQ GM:DUSA) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for Levulan(R) (aminolevulinic acid HCl) Photodynamic Therapy (PDT) for the treatment of esophageal dysplasia. This disease occurs in some patients with Barrett's esophagus, a leading cause of esophageal cancer. The incidence of esophageal cancer is one of the most rapidly growing in the U.S., with more than 11,000 new diagnoses each year. Patients diagnosed with high grade dysplasia are at high risk for developing esophageal cancer and currently have limited treatment options.

"We are pleased to receive orphan drug designation for Levulan" said Robert Doman, DUSA's President and Chief Operating Officer. "We believe that Levulan, in combination with our proprietary endoscopic light delivery system, is ideal for this significant unmet medical need and we are excited that it may someday provide patients at high risk of developing esophageal cancer with an effective and well tolerated therapeutic alternative."

Independent investigator clinical studies have reported that treatment of dysplasia with ALA PDT may help avoid the need for the removal of the esophagus and its associated morbidity. Findings from the study, "Low Incidence of Esophageal Adenocarcinoma Following Optimal Regimen of ALA PDT for High Grade Dysplasia in Barrett's Esophagus," will be presented at the Digestive Disease Week (DDW) meeting in Washington, D.C. on Sunday, May 20, 2007.

"This is a potential breakthrough for Barrett's patients and we've demonstrated this treatment can work effectively," says Laurance Lovat, M.D., senior lecturer and consultant gastroenterologist, University College Hospital in Lo
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:7/23/2014)... 2014  Dompe, a leader in R&D for new therapeutic ... (Recombinant Human Nerve Growth Factor) has been designated as an ... The candidate drug, developed by the research ... the treatment of neurotrophic keratitis, a degenerative corneal disease that ... is currently without a cure. This is the second orphan ...
(Date:7/23/2014)... 23, 2014  ArmaGen, a privately held biotechnology ... severe neurological disorders, announced today that it has ... with Shire plc to develop AGT-182, an investigational ... both the central nervous system (CNS) and somatic ... MPS II, Hunter syndrome is a rare, severe, ...
(Date:7/23/2014)... 23, 2014 Rolta ... für Sadara Chemical Company (Sadara) erhalten zu ... innerhalb des integrierten Chemiekomplexes von Sadara in ... scope im Wert von mehreren Millionen Dollar ... dar, dessen Wert sich ebenfalls auf mehrere ...
Breaking Medicine Technology:Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 2Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 3Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 4ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome 2ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome 3Rolta gewinnt Follow-on Award für Engineering Systems für Sadara, Saudi-Arabien im Wert von mehreren Millionen Dollar 2Rolta gewinnt Follow-on Award für Engineering Systems für Sadara, Saudi-Arabien im Wert von mehreren Millionen Dollar 3Rolta gewinnt Follow-on Award für Engineering Systems für Sadara, Saudi-Arabien im Wert von mehreren Millionen Dollar 4
... Ontario, Canada, Oct. 27, 2011 Valeant Pharmaceuticals International, Inc. ... of 8,523,517 additional common shares of Afexa Life Sciences Inc. ... of the offer by its wholly-owned subsidiary 1625907 Alberta Ltd. ... of Afexa. As all of the conditions to the offer ...
... and SYDNEY, Oct. 27, 2011 HeartWare International, Inc. ... innovator of less invasive, miniaturized circulatory support technologies that ... announced revenues of $21.3 million for the third quarter ... increase from $13.8 million in revenues for the same ...
Cached Medicine Technology:Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization 2Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization 3HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010 2HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010 3HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010 4HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010 5HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010 6
(Date:7/23/2014)... Low enrollment and higher-than-expected administrative ... come up with alternative means to becoming self-sustaining. ... to accomplish this in the July 17 issue ... (HEX). , “We never expected the operating budgets ... Condeluci, an attorney at the law firm Venable ...
(Date:7/23/2014)... DBC Pri-Med LLC , the leading ... more than 260,000 clinicians and the University of South ... national continuing medical education (CME) curriculum to educate and ... ultrasound and how to utilize these technologies at the ... Carolina School of Medicine will deliver its first education ...
(Date:7/23/2014)... TeraGanix has recently announced the ... located only 4.5 miles off of highway I-8. The new ... accessibility for businesses in the Arizona region that use its ... Its Casa Grande location is only 1 hour away from ... from Phoenix. With over 26 million acres of agricultural ...
(Date:7/23/2014)... VA (PRWEB) July 23, 2014 According ... residential real estate transactions throughout the region, the ... trends in June. Homes are selling quickly throughout the ... parts of the region. The Northern Virginia market includes ... Prince William counties. , The Northern Virginia region saw ...
(Date:7/23/2014)... Townsend Security, a leading authority in data ... security solutions now support two factor authentication. This major ... relying on passwords as their only authentication mechanism. , ... Two Factor Authentication software with the following Alliance ... Alliance AES/400 – High performance, NIST validated AES encryption ...
Breaking Medicine News(10 mins):Health News:Industry Observers Tell AIS They Predict Changes to Exchange User Fees, Platforms 2Health News:Industry Observers Tell AIS They Predict Changes to Exchange User Fees, Platforms 3Health News:Pri-Med and the University of South Carolina School of Medicine Launch National Ultrasound Education Initiative for Primary Care Clinicians 2Health News:Pri-Med and the University of South Carolina School of Medicine Launch National Ultrasound Education Initiative for Primary Care Clinicians 3Health News:TeraGanix Opens New Arizona-Based Agricultural Products Supply Facility 2Health News:TeraGanix Opens New Arizona-Based Agricultural Products Supply Facility 3Health News:Northern Virginia Real Estate Company Pasquali Realty Group Announces Median Sale Price Increased in the Region in June 2014 2Health News:Townsend Security Brings Two Factor Authentication to Leading IBM i Security Solutions 2
... April 24 Foundation for,Biomedical Research (FBR) Board Chairman ... the highest civilian honor Congress can,bestow, on Wednesday., ... the world of science,are few, but they are iconic ... said President George W. Bush. "Today we gather to ...
... and Employment,Discrimination, BAYSIDE, N.Y., April 24 ... hailed today,s vote in the,United States Senate ... (GINA), to ban genetic discrimination in,health insurance ... GINA,in April 2007., "TSA has worked ...
... First Patient Receives Cimzia(R) Dose through CIMplicity(TM) within Two ... ... April 24 UCB announced today the launch of its,CIMplicity(TM) ... to severe Crohn,s disease. CIMplicity(TM) provides,Cimzia(R) patients and their caregivers ...
... at Long Beach Veterans Administration Hospital, LONG ... Administration will honor Dr. Richard Merkin, President of,Heritage ... of American,war veterans. The VA, in collaboration with ... research study aimed at,examining diabetic ulcers in veterans. ...
... at 11:00,am, Family Research Council will present a lecture ... Health Policy Studies. Mr.,Moffit will discuss why health care ... applications in medicine, e.g. the,right to choose a pro-life ... the life of a loved one. To have these ...
... of Seniors Act, WASHINGTON, April 24 The ... to preventing,unintentional home injuries, applauds today,s enactment of the ... President Bush yesterday, comes,at a critical time when each ... and about 30 percent of those who fall require ...
Cached Medicine News:Health News:Michael E. DeBakey Receives Congressional Gold Medal 2Health News:Tourette Syndrome Association Applauds the Passage of Genetic Information Nondiscrimination Act 2Health News:UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers 2Health News:UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers 3Health News:UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers 4Health News:UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers 5Health News:UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers 6Health News:UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers 7Health News:Veterans Honor Dr. Richard Merkin During Research Week 2Health News:President Signs Elder Falls Bill Into Law 2
... The Veris physiological monitor offers a comprehensive ... specifically designed for pediatric and neonate patients, ... to 3T. Veris is the first MR ... of pediatric and neonate patient monitoring. The ...
The SonoSite MicroMaxx gives you big machine performance in a lightweight package. This laptop-sized, durable unit represents the technology crossover point between hand-carried ultrasound and larger...
The IDS Gamma-B 25-Hydroxy Vitamin D kit is a conventional liquid phase radioimmunoassay intended for the quantitative determination of 25-hydroxy vitamin D (25-OHD) and other hydroxylated metabolite...
... is a fully automated ... for clotting, photometric and ... tests.The medium-throughput analyser offers ... tubes, 45 reagents onboard, ...
Medicine Products: